{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:57:09Z","timestamp":1785470229557,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Several osteoanabolic agents have been developed to build new bone more efficiently than anti-resorptive drugs. Among them, romosozumab, an anti-sclerostin antibody, is a potent pharmacological tool to prevent fractures in osteoporosis patients. The efficacy of romosozumab in preventing osteoporotic fractures is robust. However, there remains a concern about increased cardiovascular (CV) adverse events related to romosozumab. Available data have been reviewed to address this concern.\n<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Published articles on romosozumab of which pivotal randomized controlled trials (RCTs), meta-analyses of RCTs, pharmacovigilance investigations, and retrospective observational clinical studies using real-world data were collected through PubMed and other available tools.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Meta-analyses of RCTs of romosozumab compared to placebo and other anti-osteoporosis drugs have left room for controversy in the CV safety of romosozumab. Investigations of the real-world data also provide no conclusive evidence in this issue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00774-025-01580-4","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T20:30:28Z","timestamp":1737145828000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular safety of osteoanabolic agents"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"1580_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy","year":"2001","unstructured":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"1580_CR2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","volume":"20","author":"BL Riggs","year":"2005","unstructured":"Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177\u2013184","journal-title":"J Bone Miner Res"},{"key":"1580_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01536-0","author":"K Ebina","year":"2024","unstructured":"Ebina K, Etani Y, Noguchi T, Nakata K, Okada S (2024) Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. https:\/\/doi.org\/10.1007\/s00774-024-01536-0","journal-title":"J Bone Miner Metab"},{"key":"1580_CR4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 316:722\u2013733","journal-title":"JAMA."},{"key":"1580_CR5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Matsumoto T (2021) Sclerostin: from bench to bedside. J Bone Miner Metab 39:332\u2013340","journal-title":"J Bone Miner Metab"},{"key":"1580_CR6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1580_CR7","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/jcm10081660","volume":"10","author":"AV Kvist","year":"2021","unstructured":"Kvist AV, Faruque J, Vallejo-Yag\u00fce E, Weiler S, Winter EM, Burden AM (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the us food and drug administration adverse event reporting system (FAERS). J Clin Med 10:1660","journal-title":"J Clin Med"},{"key":"1580_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14740338.2023.2130891","volume":"22","author":"Z Chen","year":"2023","unstructured":"Chen Z, Li M, Li S, Li Y, Wu J, Qiu K, Yu X, Huang L, Chen G (2023) A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab. Expert Opin Drug Saf 22:339\u2013342","journal-title":"Expert Opin Drug Saf"},{"key":"1580_CR9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae173","author":"J Stokar","year":"2024","unstructured":"Stokar J, Szalat A (2024) Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae173","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/87551225221144960","volume":"39","author":"K Kotake","year":"2023","unstructured":"Kotake K, Mitsuboshi S, Omori Y, Kawakami Y, Kawakami Y (2023) Evaluation of risk of cardiac or cerebrovascular events in romosozumab users focusing on comorbidities: analysis of the Japanese adverse drug event report database. J Pharm Technol 39:23\u201328","journal-title":"J Pharm Technol"},{"key":"1580_CR11","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","volume":"105","author":"F Cosman","year":"2020","unstructured":"Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SR (2020) cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial. J Clin Endocrinol Metab 105:3384\u20133395","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","volume":"106","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL, Hofbauer LC, Forfar JC (2021) Cardiovascular safety and sclerostin inhibition. J Clin Endocrinol Metab 106:1845\u20131853","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1161\/ATVBAHA.119.312371","volume":"39","author":"K Asadipooya","year":"2019","unstructured":"Asadipooya K, Weinstock A (2019) Cardiovascular outcomes of romosozumab and protective role of alendronate. Arterioscler Thromb Vasc Biol 39:1343\u20131350","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1580_CR14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1136370","volume":"315","author":"A Mani","year":"2007","unstructured":"Mani A, Radhakrishnan J, Wang H, Mani A, Mani M-A, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278\u20131282","journal-title":"Science"},{"key":"1580_CR15","doi-asserted-by":"publisher","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","volume":"12","author":"J Bovijn","year":"2020","unstructured":"Bovijn J, Krebs K, Chen C-Y, Boxall R, Censin JC et al (2020) Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. 12:eaay6570. https:\/\/doi.org\/10.1126\/scitranslmed.aay6570","journal-title":"Sci Transl Med."},{"key":"1580_CR16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00198-021-06271-0","volume":"33","author":"JJ Jacob","year":"2022","unstructured":"Jacob JJ, Paul TV (2022) Romosozumab and cardiovascular safety\u2014should we learn lessons from 3 pioglitazone? Osteoporos Int 33:1397\u20131399","journal-title":"Osteoporos Int"},{"key":"1580_CR17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jbmr.4287","volume":"36","author":"G Holdsworth","year":"2021","unstructured":"Holdsworth G, Staley JR, Hall P, van Koeverden I, Vangjeli C, Okoye R, Boyce RW, Turk JR, Armstrong M, Wolfreys A, Pasterkamp G (2021) Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans. J Bone Miner Res 36:1326\u20131339","journal-title":"J Bone Miner Res"},{"key":"1580_CR18","first-page":"e187","volume":"42","author":"J Golledge","year":"2022","unstructured":"Golledge J, Thanigaimani S (2022) Role of sclerostin in cardiovascular disease. Arterioscler Thromb Vasc Biol 42:e187\u2013e202","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1580_CR19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1580_CR20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/14740338.2022.2160445","volume":"21","author":"IR Reid","year":"2022","unstructured":"Reid IR (2022) What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab? Exert Opin Drug Saf 21:1441\u20131443","journal-title":"Exert Opin Drug Saf"},{"key":"1580_CR21","unstructured":"European Medicines Agency\u2014Science Medicines Health, (CHMP) CfMPfHU. (2019) Assessment Report\u2014Evenity (international non- proprietary name: romosozumab). EMA\/26554\/2020\u2014 EMEA\/H\/C\/004465\/0000. Accessed February 17, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/evenity-epar-public-assessment-report_en.pdf"},{"key":"1580_CR22","doi-asserted-by":"publisher","first-page":"174550572211255","DOI":"10.1177\/17455057221125577","volume":"18","author":"SY Lim","year":"2022","unstructured":"Lim SY (2022) Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk. Womens Health 18:174550572211255. https:\/\/doi.org\/10.1177\/17455057221125577","journal-title":"Womens Health"},{"key":"1580_CR23","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"CW Sing","year":"2018","unstructured":"Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, Chan EW, Kung AW, Wong IC, Cheung CL (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33:1422\u20131434","journal-title":"J Bone Miner Res"},{"key":"1580_CR24","doi-asserted-by":"publisher","first-page":"d481","DOI":"10.1210\/clinem\/dgaa481","volume":"105","author":"AJ Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez AJ, Ernst MT, Nybo M, Prieto-Alhambra D, Ebeling PR, Hermann AP, Abrahamsen B (2020) Oral bisphosphonate use reduces cardiovascular events in a cohort of danish patients referred for bone mineral density. J Clin Endocrinol Metab 105:d481. https:\/\/doi.org\/10.1210\/clinem\/dgaa481","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR25","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","volume":"103","author":"TJ Bunch","year":"2009","unstructured":"Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lapp\u00e9 DL, Osborn JS, Day JD (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824\u2013828","journal-title":"Am J Cardiol"},{"key":"1580_CR26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","volume":"252","author":"G Kranenburg","year":"2016","unstructured":"Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W (2016) Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-1 analysis. Atherosclerosis 252:106\u2013115","journal-title":"Atherosclerosis"},{"key":"1580_CR27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","volume":"179","author":"SR Cummings","year":"2019","unstructured":"Cummings SR, Lui L-Y, Eastell R, Allen IE (2019) Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 179:1491\u20131500","journal-title":"JAMA Intern Med"},{"key":"1580_CR28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","volume":"31","author":"SR Cummings","year":"2020","unstructured":"Cummings SR, McCulloch C (2020) Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int 31:1019\u20131021","journal-title":"Osteoporos Int"},{"key":"1580_CR29","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR30","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"1580_CR31","doi-asserted-by":"crossref","first-page":"116610","DOI":"10.1016\/j.bone.2022.116610","volume":"167","author":"AH Seeto","year":"2023","unstructured":"Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodr\u00edguez AJ (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post- menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610","journal-title":"Bone"},{"key":"1580_CR32","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/os.13136","volume":"13","author":"A Tian","year":"2021","unstructured":"Tian A, Jia H, Zhu S, Lu B, Li Y, Ma J, Ma X (2021) Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. Orthop Surg 13:1941\u20131950","journal-title":"Orthop Surg"},{"key":"1580_CR33","doi-asserted-by":"crossref","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C, Rohde JF, Ussing A et al (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 381:e068033","journal-title":"BMJ"},{"key":"1580_CR34","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","volume":"130","author":"F Lv","year":"2020","unstructured":"Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone 130:115121","journal-title":"Bone"},{"key":"1580_CR35","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A (2020) Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol 39:3261\u20133276","journal-title":"Clin Rheumatol"},{"key":"1580_CR36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5594","volume":"32","author":"W Huang","year":"2023","unstructured":"Huang W, Nagao M, Yonemoto N, Guo S, Tanigawa T, Nishizaki Y (2023) Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials (CDM-J). Pharmacoepidemiol Drug Saf 32:671\u2013684","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1580_CR37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"1580_CR38","unstructured":"Astellas Pharma. Results of the post-marketing survey of Evenity [Internet]. Tokyo, Japan: Astellas Pharma; 2020 [cited 2020 Mar 9]. Available from: https:\/\/amn.astellas.jp\/jp\/di\/list\/evn\/index_evn.html. Japanese."},{"key":"1580_CR39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.afos.2021.09.002","volume":"7","author":"Y Takeuchi","year":"2021","unstructured":"Takeuchi Y (2021) Romosozumab and cardiovascular safety in Japan. Osteoporos Sarcopenia 7:89\u201391","journal-title":"Osteoporos Sarcopenia"},{"key":"1580_CR40","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1253\/circj.CJ-17-0177","volume":"81","author":"N Takashima","year":"2017","unstructured":"Takashima N, Arima H, Kita Y, Fujii T, Miyamatsu N, Komori M, Sugimoto Y, Nagata S, Miura K, Nozaki K (2017) Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese- Shiga stroke registry. Circ J 81:1636\u20131646","journal-title":"Circ J"},{"key":"1580_CR41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/aje\/kwn064","volume":"167","author":"N Rumana","year":"2008","unstructured":"Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, Tomioka N, Okayama A, Nakamura Y, Abbott RD, Ueshima H (2008) Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990\u20132001. Am J Epidemiol 167:1358\u20131364","journal-title":"Am J Epidemiol"},{"key":"1580_CR42","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1359\/JBMR.050711","volume":"20","author":"LB Tank\u00f3","year":"2005","unstructured":"Tank\u00f3 LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912\u20131920","journal-title":"J Bone Miner Res"},{"key":"1580_CR43","doi-asserted-by":"publisher","first-page":"dgae173","DOI":"10.1210\/clinem\/dgae173","volume":"14","author":"J Stokar","year":"2024","unstructured":"Stokar J, Szalat A (2024) Cardiovascular safety of romosozumab vs. PTH analogs for osteoporosis treatment: a propensity score matched cohort study. J Clin Endocrinol Metab 14:dgae173. https:\/\/doi.org\/10.1210\/clinem\/dgae173","journal-title":"J Clin Endocrinol Metab"},{"key":"1580_CR44","unstructured":"Administration USFaD. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. Accessed September 1, 2023, 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture"},{"key":"1580_CR45","unstructured":"Health EMA-SM. Approval of the marketing authorisation for Evenity (romosozumab). Re-examination leads to recommendation to approve. 2019. EMA\/565564\/2019\u2014EMEA\/H\/C\/004465. Accessed February 18, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-approval-marketing-authorisation-evenity-romosozumab_en.pdf"},{"key":"1580_CR46","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00198-024-07255-6","volume":"35","author":"S Masuda","year":"2024","unstructured":"Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K (2024) Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int 35:2165\u20132174","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01580-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T02:53:14Z","timestamp":1743475994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01580-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01580-4","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. T. has disclosed that he received research grants from Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Daiichi-Sankyo Inc., and is a member of the speakers\u2019 bureau for Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Inc., Teijin Pharma Ltd., Amgen Inc., Astellas Pharma Inc., and Asahi Kasei Pharma Corp.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}